Spots Global Cancer Trial Database for Open Label Study of BAY1082439 in Patients With Advanced Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Open Label Study of BAY1082439 in Patients With Advanced Cancer
Official Title: An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1082439 Given Once Daily Continuously or in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Study ID: NCT01728311
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the safety, tolerability and the pharmacokinetics of BAY1082439
Detailed Description:
Keywords
Eligibility
Minimum Age: 21 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Seoul, , Korea, Republic of
, Seoul, , Korea, Republic of
, Singapore, , Singapore
, Singapore, , Singapore
, Taipei, , Taiwan
Contact Details
Name: Bayer Study Director
Affiliation: Bayer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
